June 4th, 2026 | 07:45 CEST
Takeover Fever! BioNxt Solutions, Delivery Hero, and Commerzbank in the Spotlight: How Investors Can Benefit!
The entry of a strategic investor or the prospect of a takeover regularly leads to significant price surges and even massive revaluations. The momentum is enormous; the global market for mergers and acquisitions has reached new records. Especially during periods of technological upheaval, geopolitical realignment, and increasing competitive pressure, companies are increasingly turning to acquisitions to secure growth, resources, or market share. In this context, there are exciting and lucrative developments for investors at BioNxt Solutions, Delivery Hero, and Commerzbank. The investment case for BioNxt Solutions is particularly compelling. The Canadian company aims to bring an alternative to weight-loss injections to market. If successful, this could create a billion-dollar business and attract acquirers. How should investors position themselves?
time to read: 3 minutes | Author: Carsten Mainitz
ISIN: Bionxt Solutions Inc. | CA0909741062 | CSE:BNXT , OTCQB: BNXTF , DELIVERY HERO SE NA O.N. | DE000A2E4K43 , COMMERZBANK AG | DE000CBK1001
Table of contents:
Author
Carsten Mainitz
The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.
Tag cloud
Shares cloud
BioNxt Solutions: A Potential Alternative to Weight-Loss Injections Opens Up a Multi-Billion-Dollar Market
With its proprietary platforms, the Canadian life sciences company focuses on next-generation drug delivery systems, diagnostic screening technologies, and the development of pharmaceutical active ingredients.
Its portfolio includes sublingual thin films, transdermal patches, oral tablets, and a new platform for targeted chemotherapy. The patient is at the core of its approach. The company delivers patient-friendly, needle-free drug delivery technologies that aim to improve comfort, portability, and treatment adherence. This is a key differentiating factor.
A central focus of its activities is oral dissolvable film (ODF) technologies, in which active ingredients are administered as fast-dissolving films through the oral mucosa. This allows for easier administration of medication while potentially improving bioavailability.
The company recently announced a key milestone. The program for orally dissolving semaglutide films (ODF), in collaboration with the German drug development partner Gen-Plus, has entered the active pharmaceutical development phase.
With this step, the Canadian company is expanding into the rapidly growing global market for GLP-1 therapies such as semaglutide. Until now, the company had primarily focused on neurological and autoimmune diseases. This development marks its transition toward a broader drug delivery platform company.
According to the company, the first phase of the semaglutide development program is expected to last six to nine months. Semaglutide is a GLP-1 receptor agonist originally developed for the treatment of type 2 diabetes, but it is now best known for its strong weight-loss effects.
The market for "weight-loss injections" is a multi-billion-dollar business and one of the fastest-growing segments in the pharmaceutical industry, with established players such as Novo Nordisk already well positioned. If oral administration proves successful, the Canadian company could become an attractive licensing or acquisition target. The company is currently valued at just under CAD 50 million at a share price of around CAD 0.40. This valuation does not reflect the enormous market potential.
Delivery Hero: Uber is Ramping Up its Investment Significantly
The company is one of the world's largest delivery platforms for food, groceries, and everyday products, operating in around 70 countries. Its business model is based on delivery fees, commissions from restaurants, and, increasingly, quick-commerce offerings for groceries and daily necessities.
The global delivery market is undergoing a wave of consolidation. Size is becoming increasingly important because it enables economies of scale in technology, logistics, and marketing. In this context, it was a logical step for Uber to recently increase its stake in the German company further. The share has nearly doubled in the last four weeks.
Including securities instruments, Uber has secured access to voting rights of nearly 37%. At the same time, another major shareholder, Aspex Fund, reduced its stake from 14.55% to 7.56%. By acquiring Delivery Hero, Uber could significantly strengthen its market position and gain access to numerous markets.
Commerzbank: Independence Is Better
Commerzbank is currently at the center of one of Europe's biggest takeover battles. Italy's UniCredit has now increased its stake to more than 34% of the share capital and holds additional derivative positions.
But the financial institution is resisting a takeover and has advised its shareholders not to accept the offer, as it does not include an appropriate takeover premium and does not reflect the company's actual value.
To make its independence more attractive, the bank has raised its profitability targets and announced job cuts. The Italians' courtship has benefited the stock price in the past. The figures also show that the major bank's business is running smoothly. It remains exciting.
Investments by strategic investors and takeover speculation clearly create additional value for shareholders. This can be seen in examples as diverse as Delivery Hero and Commerzbank. **BioNxt Solutions could also emerge as a potential takeover candidate in the future. The Canadian company is developing a range of innovative solutions and proprietary platforms. Its portfolio is expanding, and commercialization has already begun in certain areas. If BioNxt Solutions' approach succeeds in establishing itself as an alternative to weight-loss injections, it could open up a multi-billion-dollar market opportunity. At present, however, the company's share price does not appear to reflect this potential.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
